Uniqure NV
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.53
- Today's High:
- $7.895
- Open Price:
- $7.88
- 52W Low:
- $7.4
- 52W High:
- $28.255
- Prev. Close:
- $7.88
- Volume:
- 1166377
Company Statistics
- Market Cap.:
- $375.91 million
- Book Value:
- 7.407
- Revenue TTM:
- $111.94 million
- Operating Margin TTM:
- -148.36%
- Gross Profit TTM:
- $-87370000
- Profit Margin:
- -166.83%
- Return on Assets TTM:
- -12.63%
- Return on Equity TTM:
- -44.47%
Company Profile
Uniqure NV had its IPO on 2007-06-20 under the ticker symbol QURE.
The company operates in the Healthcare sector and Biotechnology industry. Uniqure NV has a staff strength of 501 employees.
Stock update
Shares of Uniqure NV opened at $7.88 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.53 - $7.9, and closed at $7.54.
This is a -4.31% slip from the previous day's closing price.
A total volume of 1,166,377 shares were traded at the close of the day’s session.
In the last one week, shares of Uniqure NV have slipped by -13.53%.
Uniqure NV's Key Ratios
Uniqure NV has a market cap of $375.91 million, indicating a price to book ratio of 2.6144 and a price to sales ratio of 17.5893.
In the last 12-months Uniqure NV’s revenue was $111.94 million with a gross profit of $-87370000 and an EBITDA of $-156528000. The EBITDA ratio measures Uniqure NV's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Uniqure NV’s operating margin was -148.36% while its return on assets stood at -12.63% with a return of equity of -44.47%.
In Q2, Uniqure NV’s quarterly earnings growth was a negative -18.2% while revenue growth was a positive 387.3%.
Uniqure NV’s PE and PEG Ratio
- Forward PE
- 27.933
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-3.96 per share while it has a forward price to earnings multiple of 27.933 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Uniqure NV’s profitability.
Uniqure NV stock is trading at a EV to sales ratio of 13.015 and a EV to EBITDA ratio of -7.3646. Its price to sales ratio in the trailing 12-months stood at 17.5893.
Uniqure NV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $942.77 million
- Total Liabilities
- $68.36 million
- Operating Cash Flow
- $45.83 million
- Capital Expenditure
- $1.07 million
- Dividend Payout Ratio
- 0%
Uniqure NV ended 2024 with $942.77 million in total assets and $0 in total liabilities. Its intangible assets were valued at $942.77 million while shareholder equity stood at $353.32 million.
Uniqure NV ended 2024 with $0 in deferred long-term liabilities, $68.36 million in other current liabilities, 2877000.00 in common stock, $-727632000.00 in retained earnings and $26.02 million in goodwill. Its cash balance stood at $513.60 million and cash and short-term investments were $628.59 million. The company’s total short-term debt was $7,780,000 while long-term debt stood at $101.11 million.
Uniqure NV’s total current assets stands at $756.96 million while long-term investments were $0.00 and short-term investments were $114.99 million. Its net receivables were $102.56 million compared to accounts payable of $9.37 million and inventory worth $10.21 million.
In 2024, Uniqure NV's operating cash flow was $45.83 million while its capital expenditure stood at $1.07 million.
Comparatively, Uniqure NV paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $7.54
- 52-Week High
- $28.255
- 52-Week Low
- $7.4
- Analyst Target Price
- $36.71
Uniqure NV stock is currently trading at $7.54 per share. It touched a 52-week high of $28.255 and a 52-week low of $28.255. Analysts tracking the stock have a 12-month average target price of $36.71.
Its 50-day moving average was $9.46 and 200-day moving average was $17.87 The short ratio stood at 3 indicating a short percent outstanding of 0%.
Around 729.8% of the company’s stock are held by insiders while 9076% are held by institutions.
Frequently Asked Questions About Uniqure NV
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.